| 1 |
Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update[J]. Ther Adv Respir Dis, 2018, 12: 1753466618808660.
|
| 2 |
Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: the diagnostic separation of transudates and exudates[J]. Ann Intern Med, 1972, 77(4): 507-513.
|
| 3 |
Chinchkar NJ, Talwar D, Jain SK. A stepwise approach to the etiologic diagnosis of pleural effusion in respiratory intensive care unit and short-erm evaluation of treatment[J]. Lung India, 2015, 32(2): 107-115.
|
| 4 |
Porcel JM, Light RW. Pleural effusions[J]. Dis Mon, 2013, 59(2): 29-57.
|
| 5 |
Porcel JM, Azzopardi M, Koegelenberg CF, et al. The diagnosis of pleural effusions[J]. Expert Rev Respir Med, 2015, 9(6): 801-815.
|
| 6 |
Morales-Rull JL, Bielsa S, Conde-Martel A, et al. Pleural effusions in acute decompensated heart failure: prevalence and prognostic implications[J]. Eur J Intern Med 2018, 52: 49-53.
|
| 7 |
曾灏，田攀文. 恶性胸腔积液的诊断研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2021, 14(2): 247-249.
|
| 8 |
Light RW. The Light criteria: the beginning and why they are useful 40 years later[J]. Clin Chest Med, 2013, 34(1): 21-26.
|
| 9 |
谭慧，王璞. 免疫指标在结核性胸腔积液诊断中的研究进展 [J]. 西部医学，2024, 36(1): 152-156.
|
| 10 |
Porcel JM, Vives M, Cao G, et al. Measurement of pro-brain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure[J]. Am J Med, 2004, 116(6): 417-420.
|
| 11 |
Kolditz M, Halank M, Schiemanck CS, et al. High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions[J]. Eur Respir J, 2006, 28(1): 144-150.
|
| 12 |
Light RW. Use of pleural fluid N-terminal-pro-brain natriuretic peptide and brain natriuretic peptide in diagnosing pleural effusion due to congestive heart failure[J]. Chest, 2009, 136(3): 656-658.
|
| 13 |
Porcel JM. Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure[J]. Curr Opin Pulm Med, 2011, 17(4): 215-219.
|
| 14 |
Nguyen Trung ML, Tridetti J, Ancion A，et al. Peptides natriurétiques dans l′insuffisance cardiaque [Natriuretic peptides in heart failure][J]. Rev Med Liege, 2020, 75(10): 644-648.
|
| 15 |
Beukes A, Shaw JA, Diacon AH, et al. The utility of pleural fluid lactate dehydrogenase to adenosine deaminase ratio in pleural tuberculosis[J]. Respiration, 2021, 100(1): 59-63.
|
| 16 |
Maranhão BHF, da Silva Junior CT, Barillo JL, et al. Diagnostic accuracy with total adenosine deaminase as a biomarker for discriminating pleural transudates and exudates in a population-based cohort study[J]. Dis Markers, 2021, 2021: 6648535.
|
| 17 |
Jadhav AA, Bardapurkar JS. Diagnostic value of adenosine deaminase to differentiate exudates and transudates[J]. Indian J Physiol Pharmacol, 2007, 51(2): 170-174.
|
| 18 |
Atalay F, Ernam D, Hasanoglu HC, et al. Pleural adenosine deaminase in the separation of transudative and exudative pleural effusions[J]. Clin Biochem, 2005, 8(12): 1066-1070.
|
| 19 |
Alonso JC. Pleural effusion in liver disease[J]. Semin Respir Crit Care Med, 2010, 31(6): 698-705.
|
| 20 |
Bielsa S, Porcel JM, Castellote J, et al. Solving the Light's criteria misclassification rate of cardiac and hepatic transudates[J]. Respirology, 2012，17(4): 721-726.
|
| 21 |
Mangaraj M, Kumari S, Nanda R, et al. Pleural fluid MDA and serum-effusion albumin gradient in pleural effusion[J]. Indian J Clin Biochem, 2008, 23(1): 81-84.
|
| 22 |
Kummerfeldt CE, Chiuzan CC, Huggins JT, et al. Improving the predictive accuracy of identifying exudative effusions[J]. Chest, 2014, 145(3): 586-592.
|
| 23 |
Sharma K, Fultariya L, Reddy Mallimala P, et al. Comparison of the efficacy of Light′s Criteria with serum-effusion albumin gradient and pleural effusion glucose[J]. Cureus, 2023, 15(8): e43319.
|
| 24 |
Antus B. Oxidative stress markers in sputum[J]. Oxid Med Cell Longev, 2016, 2016: 2930434.
|
| 25 |
Papageorgiou E, Kostikas K, Kiropoulos T, et al. Increased oxidative stress in exudative pleural effusions: a new marker for the differentiation between exudates and transudates？[J]. Chest, 2005, 128(5): 3291-3297.
|
| 26 |
Wang S, Wang F, Kong F, et al. Effect of supplementing different levels of L-Glutamine on holstein calves during weaning[J]. Antioxidants (Basel), 2022, 11(3): 542.
|
| 27 |
Narsimha RY, Anil KV, Srinivas M．？Study on oxidative metabolic changes to differentiate exudative from transudative pleural effusions[J]. S J Pharm Sci, 1(1): 38-43.
|
| 28 |
Gormeli Kurt N, Gokhan S, Erel O, et al. The role of pleural fluid thiol/disulphide homoeostasis in the differentiation between transudative and exudative pleural effusions[J]. Int J Clin Pract, 2021, 75(4): e14051.
|
| 29 |
Gopi A, Madhavan SM, Sharma SK, et al. Diagnosis and treatment of tuberculous pleural effusion in 2006[J]. Chest, 2007, 131(3): 880-889.
|
| 30 |
Johnson RW. Inhibition of growth by pro-inflammatory cytokines: an integrated view[J]. J Anim Sci, 1997, 75(5): 1244-1255.
|
| 31 |
Harma MI, Harma M, Erel O. d-ROMs test detects ceruloplasmin, not oxidative stress[J]. Chest, 2006, 130(4): 1276.
|
| 32 |
Calikoglu M, Sezer C, Unlü A, et al. Use of acute phase proteins in pleural effusion discrimination[J]. Tuberk Toraks, 2004, 52(2): 122-129.
|
| 33 |
Shanthaveeranna GK, Thykadavil VG, D′souza GA. Use of pleural fluid ceruloplasmin in the differentiation of exudative and transudative pleural effusion[J]. Lung India, 2015, 32(1): 11-15.
|
| 34 |
Alexandrakis MG, Coulocheri SA, Bouros D, et al. Significance of alpha-2-macroglobulin, alpha-1-acid glycoprotein, and C-reactive protein in pleural effusion differentiation[J]. Respiration, 2000, 67(1): 30-35.
|
| 35 |
Qu SY, Zhang Y, Wu S, et al. Combined analysis of C-reactive protein in pleural fluid and serum is effective in the differential diagnosis of exudative pleural effusions[J]. Ann Transl Med, 2021, 9(14): 1183.
|
| 36 |
Kogan Y, Sabo E, Odeh M. Role of C-reactive protein in discrimination between transudative and exudative pleural effusions[J]. Diagnostics (Basel), 2021, 11(11): 2003.
|
| 37 |
赵伟和，蔡挺，黄建达，等. 五种急性炎性蛋白在胸腔积液诊断中的价值[J]. 中华结核和呼吸杂志，2000, (12): 748.
|
| 38 |
Tripathi A, Shrinet K, Kumar A. HMGB1 protein as a novel target for cancer[J]. Toxicol Rep, 2019, 6: 253-261.
|
| 39 |
Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung[J]. J Biomed Biotechnol, 2010, 2010: 917108.
|
| 40 |
Sim YS, Kim DG, Shin TR. The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion[J]. J Thorac Dis, 2016, 8(7): 1731-1737.
|
| 41 |
Kotsiou OS, Jagirdar RM, Papazoglou ED, et al. HMGB1/sRAGE levels differ significantly between transudates and exudates[J]. Cytokine, 2021, 141: 155469.
|
| 42 |
Chao MR, Chang YJ, Shih YM, et al. Elevated nitrite/nitrate ratio as a potential biomarker for the differential diagnosis of pleural effusions[J]. Antioxidants (Basel), 2022, 11(7): 1327.
|
| 43 |
Leers MP, Kleinveld HA, Scharnhorst V. Differentiating transudative from exudative pleural effusion: should we measure effusion cholesterol dehydrogenase？[J]. Clin Chem Lab Med, 2007, 45(10): 1332-1338.
|
| 44 |
Santosh G, Shiva RKC, Binita B, et al. Diagnostic value of pleural cholesterol in differentiating exudative and transudative pleural effusion[J]. Ann Med Surg (Lond), 2022, 82: 104479.
|
| 45 |
Ozsu S, Gulsoy A, Karahan SC, et al. Diagnostic value of pleural effusion ischaemia-modified albumin in patients with cardiac failure[J]. Ann Clin Biochem, 2011, 48(Pt1): 45-50.
|
| 46 |
Dikensoy O, Celik N, Kul S, et al. Ischemia modified albumin in the differential diagnosis of pleural effusions[J]. Respir Med, 2011, 105(11): 1712-1717.
|